Gastroparesis Drugs Market by Drug Class, Indication, Sales Channel

KEY MARKET STATISTICS
Base Year [2023]	USD 4.37 billion
Estimated Year [2024]	USD 4.54 billion
Forecast Year [2030]	USD 6.85 billion
CAGR (%)	6.61%

The FPNV Positioning Matrix is pivotal in evaluating the Gastroparesis Drugs Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Gastroparesis Drugs Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Gastroparesis Drugs Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, AbbVie Inc., Amneal Pharmaceuticals, Inc., ANI Pharmaceuticals, Inc., AstraZeneca PLC, Atlantic Healthcare PLC, Bausch Health Companies Inc., Bristol-Myers Squibb Company, Cadila Pharmaceuticals Limited, Cairn Diagnostics, Evoke Pharma, Inc., GlaxoSmithKline PLC, Johnson & Johnson Services, Inc., Kyowa Kirin International plc, Lupin Limited, Medtronic PLC, Neurogastrx, Inc., Novartis AG, Pfizer, Inc., Processa Pharmaceuticals, Inc., Sanofi S.A., Takeda Pharmaceutical Company Limited, Theravance Biopharma, Vanda Pharmaceuticals Inc., and Viatris Inc..

Market Segmentation & Coverage

This research report categorizes the Gastroparesis Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

Drug Class
- Anti-Emetic Agents
- Botulinum Toxin Injections
- Prokinetic Agents
Indication
- Diabetic Gastroparesis
- Idiopathic Gastroparesis
- Post-surgical Gastroparesis
Sales Channel
- Offline
  - Hospitals Pharmacies
  - Retail Pharmacies
- Online
Region
- Americas
  - Argentina
  - Brazil
  - Canada
  - Mexico
  - United States
    - California
    - Florida
    - Illinois
    - New York
    - Ohio
    - Pennsylvania
    - Texas
- Asia-Pacific
  - Australia
  - China
  - India
  - Indonesia
  - Japan
  - Malaysia
  - Philippines
  - Singapore
  - South Korea
  - Taiwan
  - Thailand
  - Vietnam
- Europe, Middle East & Africa
  - Denmark
  - Egypt
  - Finland
  - France
  - Germany
  - Israel
  - Italy
  - Netherlands
  - Nigeria
  - Norway
  - Poland
  - Qatar
  - Russia
  - Saudi Arabia
  - South Africa
  - Spain
  - Sweden
  - Switzerland
  - Turkey
  - United Arab Emirates
  - United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Gastroparesis Drugs Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Gastroparesis Drugs Market?

3. What are the technology trends and regulatory frameworks in the Gastroparesis Drugs Market?

4. What is the market share of the leading vendors in the Gastroparesis Drugs Market?

5. Which modes and strategic moves are suitable for entering the Gastroparesis Drugs Market?

Product Code: MRR-C002B1C99722

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

4.1. Introduction
4.2. Gastroparesis Drugs Market, by Region

5. Market Insights

5.1. Market Dynamics
- 5.1.1. Drivers
  - 5.1.1.1. Increase in diabetic population across the globe
  - 5.1.1.2. Rising investment in healthcare infrastructure to enhance healthcare accessibility
- 5.1.2. Restraints
  - 5.1.2.1. High cost of raw materials used in formulation of hyperlipidemia drugs
- 5.1.3. Opportunities
  - 5.1.3.1. Continuous research & development activities for new drug development
  - 5.1.3.2. Increasing drug approvals by the regulatory authorities worldwide
- 5.1.4. Challenges
  - 5.1.4.1. Severe side effects associated with the consumption of gastroparesis drugs
5.2. Market Segmentation Analysis
5.3. Market Trend Analysis
5.4. Cumulative Impact of High Inflation
5.5. Porter's Five Forces Analysis
- 5.5.1. Threat of New Entrants
- 5.5.2. Threat of Substitutes
- 5.5.3. Bargaining Power of Customers
- 5.5.4. Bargaining Power of Suppliers
- 5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework

6. Gastroparesis Drugs Market, by Drug Class

6.1. Introduction
6.2. Anti-Emetic Agents
6.3. Botulinum Toxin Injections
6.4. Prokinetic Agents

7. Gastroparesis Drugs Market, by Indication

7.1. Introduction
7.2. Diabetic Gastroparesis
7.3. Idiopathic Gastroparesis
7.4. Post-surgical Gastroparesis

8. Gastroparesis Drugs Market, by Sales Channel

8.1. Introduction
8.2. Offline
- 8.3.1. Hospitals Pharmacies
- 8.3.2. Retail Pharmacies
8.3. Online

9. Americas Gastroparesis Drugs Market

9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States

10. Asia-Pacific Gastroparesis Drugs Market

10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam

11. Europe, Middle East & Africa Gastroparesis Drugs Market

11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom

12. Competitive Landscape

12.1. FPNV Positioning Matrix
12.2. Market Share Analysis, By Key Player
12.3. Competitive Scenario Analysis, By Key Player

13. Competitive Portfolio

13.1. Key Company Profiles
- 13.1.1. Abbott Laboratories
- 13.1.2. AbbVie Inc.
- 13.1.3. Amneal Pharmaceuticals, Inc.
- 13.1.4. ANI Pharmaceuticals, Inc.
- 13.1.5. AstraZeneca PLC
- 13.1.6. Atlantic Healthcare PLC
- 13.1.7. Bausch Health Companies Inc.
- 13.1.8. Bristol-Myers Squibb Company
- 13.1.9. Cadila Pharmaceuticals Limited
- 13.1.10. Cairn Diagnostics
- 13.1.11. Evoke Pharma, Inc.
- 13.1.12. GlaxoSmithKline PLC
- 13.1.13. Johnson & Johnson Services, Inc.
- 13.1.14. Kyowa Kirin International plc
- 13.1.15. Lupin Limited
- 13.1.16. Medtronic PLC
- 13.1.17. Neurogastrx, Inc.
- 13.1.18. Novartis AG
- 13.1.19. Pfizer, Inc.
- 13.1.20. Processa Pharmaceuticals, Inc.
- 13.1.21. Sanofi S.A.
- 13.1.22. Takeda Pharmaceutical Company Limited
- 13.1.23. Theravance Biopharma
- 13.1.24. Vanda Pharmaceuticals Inc.
- 13.1.25. Viatris Inc.
13.2. Key Product Portfolio

14. Appendix

14.1. Discussion Guide
14.2. License & Pricing